NTRA 2112

Drug Profile

NTRA 2112

Alternative Names: NTRA-2112

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nutrinia
  • Class Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastrointestinal disorders

Most Recent Events

  • 01 Oct 2016 Phase-III clinical trials in Gastrointestinal disorders (In infants) in Netherlands (PO) , NCT02510560)
  • 01 Aug 2016 Nutrinia terminates a phase trial II trial in Gastrointestinal disorders (In infants) in Israel (NCT01093638)
  • 14 Aug 2015 Nutrinia plans a phase III trial for Gastrointestinal disorders (in neonates) in USA and European Union (NCT02510560)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top